It combines an anti-HER2 humanized monoclonal antibody with approximately eight molecules of deruxtecan––a campthothecin derivative that inhibits topoisomerase I––linked through a tumor cell-internalizing peptide-containing linker [33]. Here, ERBB2 is linked to neoplasm.